摘要
目的探讨血管内皮生长因子受体2(VEGFR-2)、血小板衍生生长因子受体β(PDGFR-β)和c-MET在肝细胞癌(HCC)中表达的临床意义及对预后的影响。方法应用免疫组织化学法检测93例HCC组织中VEGFR-2、PDGFR-β和c-MET的表达,分析其与临床病理特征和预后的关系。结果 VEGFR-2、PDGFR-β和c-MET在HCC组织中的高表达率分别为86.0%、19.4%和80.6%。VEGFR-2表达与性别、HBsAg状态、分化程度、肝硬化有关(P<0.05),PDGFR-β表达与AFP、肿瘤数目、肝硬化有关(P<0.05),c-MET表达与临床病理特征无关。Cox多因素回归分析显示,65例服用索拉非尼患者的无进展生存期(PFS)与年龄(P=0.047)有关,总生存期(OS)与HBsAg(P=0.037)、AFP(P=0.015)和肿瘤大小(P=0.003)有关;PDGFR-β表达水平与OS相关(P=0.046),c-MET与PFS相关(P=0.01)。结论 VEGFR-2在HCC合并肝硬化的患者中存在高表达,PDGFR-β高表达是HCC的预后不良指标,c-MET可能是HCC患者服用索拉非尼疗效的一个预测指标。
Objective To explore the clinical significance and prognostic values of VEGFR-2,PDGFR-β and c-MET in patients with hepatocellular carcinoma（HCC）.Methods The expression of VEGFR-2,PDGFR-β and c-MET in 93 HCC patients was examined by immunohistochemistry（IHC）,and the correlation between clinical characteristics and progrosis was analyzed.Results The over-expression rates of VEGFR-2,PDGFR-β and c-MET in HCC were 86.0%,19.4% and 80.6%,respectively.The expression of VEGFR-2 was related with sex,hepatitis B surface antigen（HBsAg） status,differentiation and hepatic cirrhosis（P〈0.05）.The expression of PDGFR-β was related with α-fetoprotein（AFP）,number of tumor and hepatic cirrhosis（P〈0.05）.There was no significant relationship between the expression of c-MET and clinicopathological factors.Cox regression analysis showed that in 65 patients taking sorafenib,the progress free survival（PFS） was related to age（P=0.047）,and the overall survival（OS） was related to HBsAg（P=0.037）,AFP（P=0.015） and tumor size（P=0.003）.The expression of PDGFR-β was related with OS（P=0.046）.The expression of c-MET was related to PFS（P=0.01）.Conclusion The expression level of VEGFR-2 is higher in HCC patients with hepatic cirrhosis.PDGFR-β is a biomarker for the poor prognosis in HCC patients.c-MET may be a prognostic factor to predict the therapeutic effect of HCC patients who have taken sorafenib.
出处
《临床肿瘤学杂志》
CAS
2012年第7期609-615,共7页
Chinese Clinical Oncology
